Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1b/2 immunotherapy and targeted therapy combinations in previously treated advanced clear cell renal cell carcinoma (U03 Substudy 03B)
MOH_2020-11-02_009049Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Aug 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pembrolizumab, lenvatinib, belzutifan, mk-4830, quavonlimab and 1 more in renal cell carcinoma (RCC) (6 arms), sponsored by Merck & Co. Primary endpoints: Safety and tolerability and Efficacy. Started Aug 2020; status: completed.
02
Drugs
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on MOH_2020-11-02_009049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-11-02_009049.